LE WE PMID CA
Bisphosphonates3308Bisphosphonat

Bisphosphonates

Bone (BASKET)

Bone (Metastasis)

Cinacalcet

Fibrous dysplasia

Jaws (Osteonecrosis)

Mammary gland (Neoplasia)

Neoplasia (Tumor biology and immunology)

Osteoclasts

Osteogenesis imperfecta

Osteoporosis

Prostate (Neoplasia)

PTH (Hyperparathyreoidism BASKET)

Raloxifene

Tooth (Implantates)

2002  
1
Gastric and duodenal safety of daily alendronate.
[11966346] Arch Intern Med 162(8): 936-42 (2002)
2001  
2
2010  
3
Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect.
[20694061] Core Evid 4(-): 13-23 (2010)
1973  
4
Diphosphonates. Experimental and clinical aspects.
[4632759] J Bone Joint Surg Br 55(1): 66-86 (1973)
2008  
5
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.
[17906299] Ann Oncol 19(3): 420-32 (2008)
2007  
6
Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis.
[17591816] Ann Oncol 18 Suppl 6(-): vi168-72 (2007)
2007  
7
New developments of aminobisphosphonates: the double face of Janus.
[17591815] Ann Oncol 18 Suppl 6(-): vi164-7 (2007)
2006  
8
Management of the adverse effects associated with intravenous bisphosphonates.
[16547070] Ann Oncol 17(6): 897-907 (2006)
2006  
9
Bisphosphonates and metastatic bone disease.
[16608996] Ann Oncol 17 Suppl 2(-): ii91-95 (2006)
2003  
10
The antineoplastic role of bisphosphonates: from basic research to clinical evidence.
[14504045] Ann Oncol 14(10): 1468-76 (2003)
2007  
11
The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
[17311345] Cancer 109(6): 1090-6 (2007)
2005  
12
Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.
[15929121] Cancer 104(1): 83-93 (2005)
2003  
13
Effectiveness and cost of bisphosphonate therapy in tumor bone disease.
[12548587] Cancer 97(3 Suppl): 859-65 (2003)
2003  
14
Antitumor effects of bisphosphonates.
[12548584] Cancer 97(3 Suppl): 840-7 (2003)
2000  
15
Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies.
[10898355] Cancer 88(12 Suppl): 3080-8 (2000)
2000  
16
Cellular and molecular mechanisms of action of bisphosphonates.
[10898340] Cancer 88(12 Suppl): 2961-78 (2000)
2006  
17
Molecular mechanisms of action of bisphosphonates: current status.
[17062705] Clin Cancer Res 12(20 Pt 2): 6222s-6230s (2006)
2003  
18
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
[12855610] Clin Cancer Res 9(7): 2394-9 (2003)
2009  
19
Bisphosphonates in oncology: rising stars or fallen heroes.
[19179412] Oncologist 14(2): 181-91 (2009)
2004  
20
Toward new horizons: the future of bisphosphonate therapy.
[15459428] Oncologist 9 Suppl 4(-): 38-47 (2004)
2004  
21
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
[15459427] Oncologist 9 Suppl 4(-): 28-37 (2004)
2004  
22
Bisphosphonates: clinical experience.
[15459426] Oncologist 9 Suppl 4(-): 14-27 (2004)
2004  
23
Bisphosphonates: preclinical review.
[15459425] Oncologist 9 Suppl 4(-): 3-13 (2004)
2006  
24
Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations.
[16873332] J Am Dent Assoc 137(8): 1144-50 (2006)
2005  
25
Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge.
[16383048] J Am Dent Assoc 136(12): 1669-74 (2005)
2005  
26
Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper.
[16383047] J Am Dent Assoc 136(12): 1658-68 (2005)
1998  
27
Bisphosphonates: mechanisms of action.
[9494781] Endocr Rev 19(1): 80-100 (1998)
2006  
28
Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.
[16702591] Ann Intern Med 144(10): 753-61 (2006)
2009  
29
Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue.
[18987295] Clin J Am Soc Nephrol 4(1): 221-33 (2009)
2006  
30
Emerging anti-cancer molecular mechanisms of aminobisphosphonates.
[16601276] Endocr Relat Cancer 13(1): 7-26 (2006)
2005  
31
2007  
32
Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases.
[17396000] J Musculoskelet Neuronal Interact 7(1): 2-8 (2007)
2009  
33
Adverse effects of bisphosphonates: implications for osteoporosis management.
[19567717] Mayo Clin Proc 84(7): 632-7; quiz 638 (2009)
2008  
34
Bisphosphonates: mechanism of action and role in clinical practice.
[18775204] Mayo Clin Proc 83(9): 1032-45 (2008)
2007  
35
Bisphosphonates: mode of action and pharmacology.
[17332236] Pediatrics 119 Suppl 2(-): S150-62 (2007)
2007  
36
Bisphosphonates and osteonecrosis of the jaw.
[17500074] Rheumatology (Oxford) 46(7): 1049-51 (2007)
2009  
37
Bisphosphonate-related osteonecrosis of the jaw: a pictorial review.
[19926757] Radiographics 29(7): 1971-84 (2009)
2010  
38
Long-term use of bisphosphonates in osteoporosis.
[20173017] J Clin Endocrinol Metab 95(4): 1555-65 (2010)
2009  
39
Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.
[19193912] J Clin Endocrinol Metab 94(2): 373-81 (2009)
2006  
40
Bisphosphonate complications including osteonecrosis of the jaw.
[17124083] Hematology Am Soc Hematol Educ Program -(-): 356-60, 515 (2006)
2008  
41
Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study.
[18378544] Oncologist 13(3): 330-6 (2008)
2009  
42
Bisphosphonates and time to osteonecrosis development.
[19897878] Oncologist 14(11): 1154-66 (2009)
2005  
43
Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.
[15958534] Cancer Res 65(12): 4971-4 (2005)
2008  
44
Risks and benefits of bisphosphonates.
[18506174] Br J Cancer 98(11): 1736-40 (2008)
2006  
45
Bisphosphonates and oral pathology II. Osteonecrosis of the jaws: review of the literature before 2005.
[17072246] Med Oral Patol Oral Cir Bucal 11(6): E456-61 (2006)
2008  
46
Oral implants in patients receiving bisphosphonates: a review and update.
[19047961] Med Oral Patol Oral Cir Bucal 13(12): E755-60 (2008)
2007  
47
Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates.
[17664922] Med Oral Patol Oral Cir Bucal 12(4): E336-40 (2007)
2008  
48
Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update.
[18449117] Med Oral Patol Oral Cir Bucal 13(5): E318-24 (2008)
2010  
49
Bisphosphonates in the treatment of metabolic bone diseases.
[20485910] Arq Bras Endocrinol Metabol 54(2): 206-12 (2010)
2004  
50
A systematic review of the role of bisphosphonates in metastatic disease.
[14960258] Health Technol Assess 8(4): 1-176 (2004)
2010  
51
Ocular side effects of bisphosphonates: A case report and literature review.
[20944044] Can Fam Physician 56(10): 1015-7 (2010)
2007  
52
Use of bisphosphonates in prostate cancer: Current status.
[19675763] Indian J Urol 23(1): 51-4 (2007)
2007  
53
A review of bisphosphonate-associated osteonecrosis of the jaws and its management.
[17555652] J Can Dent Assoc 73(5): 417-22 (2007)
2002  
54
Actions of bisphosphonates in animal models of breast cancer.
[11879558] Breast Cancer Res 4(1): 35-41 (2002)
2002  
55
Direct effects of bisphosphonates on breast cancer cells.
[11879555] Breast Cancer Res 4(1): 18-23 (2002)
2011  
56
Bisphosphonates' : Indications in bone diseases other than osteoporosis.
[21681711] Tunis Med 89(6): 511-6 (2011)
2009  
57
Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges.
[19491914] Nat Rev Rheumatol 5(6): 341-6 (2009)
2011  
58
What do we know about the ocular adverse effects associated with intravenous bisphosphonates?
[21417978] Eklem Hastalik Cerrahisi 22(1): 1 (2011)
2009  
59
Bisphosphonate-associated adverse events.
[19570737] Hormones (Athens) 8(2): 96-110 (2009)
2011  
60
Tumour macrophages as potential targets of bisphosphonates.
[22005011] J Transl Med 9(-): 177 (2011)
2010  
61
Intravenous bisphosphonates for postmenopausal osteoporosis.
[21526078] J Res Med Sci 15(3): 175-84 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


  • Bisphosphonat-assoziierte Kiefernekrosen


  • Bisphosphonat

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia